







7.1.a Detail on diabetes diagnosis

	Overall	M06	M12	M18	M24	M30	M36	M42	M48
Semi-annual visits	3444	2021	-	1073 ¹	-	350	-	-	-
Diabetes, n (% visits)	95 (2.8)	61 (3.0)	-	22 (2.1)	-	12 (3.4)	-	-	-
Positive A1c and FPG	32	20	-	8	-	4	-	-	-
Positive A1c or FPG, pos. confirmatory	63	41	-	14	-	8	-	-	-
No diabetes, n	3349	1960	-	1051	-	338	-	-	-
Negative A1c and FPG	3251	1900	-	1025	-	326	-	-	-
Positive A1c or FPG, neg. confirmatory	98	60	-	26	-	12	-	-	-
Weight change (% from baseline)		-0.19%		-0.13%		-0.30%			
Annual visits	2233	-	1503 ¹	-	684	-	46	-	-
Diabetes, n (% visits)	119 (5.3)	-	85 (5.7)	-	31 (4.5)	-	3 (6.5)	-	-
Positive, met 2 criteria	46	-	33	-	11	-	2	-	-
Positive, met 1 criterion, pos. confirmatory	73	-	52	-	20	-	1	-	-
No diabetes, n	2114	-	1418	-	653	-	43	-	-
All 3 criteria negative	1993	-	1333	-	621	-	39	-	-
Met 1 criterion, neg. confirmatory	121	-	85	-	32	-	4	-	-
Weight change (% from baseline)			-0.06%		-0.11%		-0.19%		
Outside of study events by adjudication ²	22	5	7	6	2	1	1		
Total events	236	66	92	28	33	13	4		


¹ Number excludes participants who have reached the *diabetes outcome* [by D2d criteria or adjudication].

² If diabetes outcome was adjudicated before stated interval, it is shown under stated interval. For example, adjudicated outcomes between the M06 and M12 visits are shown under M12. Longitudinal analyses (when conducted) will be based on “time-to-event.”

Annual Kaplan-Meier event rate = 7.67%

Product-Limit Survival Estimates

Visit Month	At risk	Survival	Failure	Survival Standard Error	Number Failed	Number Left
0	2419	1	0	0	0	2264
6	2048	0.9714	0.0286	0.00367	59	1802
12	1532	0.9233	0.0767	0.00636	137	1328
18	1088	0.8886	0.1114	0.00793	183	941
24	692	0.856	0.144	0.00983	210	570
30	354	0.8164	0.1836	0.0128	231	230
36	46	0.7455	0.2545	0.0323	239	0




Among participants meeting DPP eligibility criteria (FPG 95-125 and 2hPG 140-199)

Annual Kaplan-Meier event rate = **10.51%**

Product-Limit Survival Estimates


Visit Month	At risk	Survival	Failure	Survival Standard Error	Number Failed	Number Left
0	1163	1	0	0	0	1078
6	977	0.9624	0.0376	0.00607	37	848
12	725	0.8949	0.1051	0.0106	89	625
18	502	0.8377	0.1623	0.0135	126	424
24	296	0.7889	0.2111	0.017	144	236
30	144	0.7246	0.2754	0.0226	159	100
36	20	0.6734	0.3266	0.0418	162	0



Missed encounters (visits and interim phone contact)

6


Study-wide = 3.9% (Last Week = 4.0%)




Missed encounters **within last 6 months** (visits and interim phone contact)

7

Study-wide = 5.0% (Last week = 5.3%)




% inactive and withdrawn participants




Labels are number of participants (inactive; withdrawn).

Inactive and Withdrawn Participants




Inactive and Withdrawn Participants

excludes those diagnosed with diabetes




Discontinuation of Study Pills

excludes participants who withdrew consent




Discontinuation of Study Pills

excludes participants who withdrew consent and participants who have met diabetes outcome




Discontinuation of Study Pills

excludes participants who withdrew consent



Discontinuation of Study Pills - Last 6 Months

excludes participants who withdrew consent



Ongoing Glycemia-Lowering Medications without D2d Diagnosis of Diabetes

15

Site	ID	RAND Date	Medication	Start date	Months in study at start	Indication	Indication, other	Adjudication outcome
South Carolina	050123	5/15/2015	metformin	9/27/2015	4	Other	pre-diabetes	Participant did not experience new-onset diabetes
Northwestern	090055	4/25/2014	metformin	4/11/2016	24	Other	prediabetes	Participant did not experience new-onset diabetes
Northwestern	090153	4/30/2015	metformin	9/12/2015	4	Other	prediabetes	Adjudication pending
Northwestern	090262	3/28/2016	Metformin	9/24/2016	6	Weight loss		Participant did not experience new-onset diabetes
HealthPartners	130289	12/29/2014	Metformin	1/24/2016	13	Diabetes		Participant did not experience new-onset diabetes
Kansas	140003	2/19/2014	Metformin	7/5/2015	16	Weight loss		Participant did not experience new-onset diabetes
Kansas	140168	5/19/2015	metformin	7/30/2016	14	Diabetes		Participant did not experience new-onset diabetes
Baylor	150082	9/25/2014	metformin	4/25/2016	19	Diabetes		Participant did not experience new-onset diabetes
UT Southwestern	170026	6/2/2014	Metformin	9/18/2014	4	Other	Diabetes prevention	Adjudication pending
UT Southwestern	170064	8/18/2015	Dulaglutide	8/20/2016	12	Other	Prediabetes	Adjudication pending
LA	190023	4/14/2014	Metformin, Pioglitazone	5/2/2016	25	Diabetes		Participant did not experience new-onset diabetes
Nebraska - VA	210041	4/30/2014	Metformin	9/29/2014	5	Other	Diabetic Prevention	Participant did not experience new-onset diabetes
Oregon	230377	12/15/2015	metformin	10/3/2016	10	Other	prediabetes	Participant did not experience new-onset diabetes

The SAS System


02/01/2017

Site	SCR visits	BAS potential	BAS visits	Awaiting BAS labs	Awaiting RAN	RAN visits	RAN goal	% of promised
Maine	370	.	173	.	.	107	125	85.6
Tufts	510	.	262	.	.	154	112	137.5
MedStar	418	.	247	.	.	159	150	106.0
Duke	375	.	229	.	.	140	150	93.3
SouthCarolina	183	.	70	.	.	32	150	21.3
Florida	362	.	122	.	.	76	150	50.7
Atlanta	263	.	226	.	.	137	180	76.1
NewYork	157	.	40	.	.	4	100	4.0
Northwestern	307	.	220	.	.	120	125	96.0
Tennessee	82	.	38	.	.	29	150	19.3
Tulane	35	.	2	.	.	2	150	1.3
Pennington	262	.	87	.	.	49	190	25.8
HealthPartners	639	.	474	.	.	318	300	106.0
Kansas	415	.	200	2	.	124	150	82.7
Baylor	209	.	82	.	.	43	150	28.7
Nebraska	559	.	296	.	.	175	126	138.9
UTSouthwestern	118	.	78	.	.	43	120	35.8
LA	260	.	143	.	.	84	120	70.0
Stanford	328	.	158	.	.	91	150	60.7
Baltimore	214	.	126	.	.	83	100	83.0
Cleveland	189	.	96	.	1	55	100	55.0
Kaiser	456	.	415	2	.	267	130	205.4
Denver	338	.	138	.	.	81	65	124.6
Lenox	84	.	52	1	.	46	25	184.0
	7133	.	3974	5	1	2419	3268	100.2

The SAS System

Site	Monthly RAN goal	RAN goal	SCR visits	BAS visits	RAN visits	SCR:RAN ratio	% of goal	1/2017 SCR visits	1/2017 BAS visits	1/2017 RAN visits	1/2017 SCR:RAN ratio	1/2017 RAN goal(%)	12/2016 SCR visits	12/2016 BAS visits	12/2016 RAN visits	12/2016 SCR:RAN ratio	12/2016 RAN goal(%)
Maine	5.2	125	370	173	107	3.5	85.6	1	1	.	.	.	2	2	2	1.0	38
Tufts	4.7	112	510	262	154	3.3	137.5	1	1	1	1.0	21	4	6	5	.8	106
MedStar	6.3	150	418	247	159	2.6	106.0	1	1	1	1.0	16	.	.	3	.	48
Duke	6.3	150	375	229	140	2.7	93.3	.	1	.	.	.	3	.	3	1.0	48
SouthCarolina	6.3	150	183	70	32	5.7	21.3	.	.	.	.	.	.	.	.	.	.
Florida	6.3	150	362	122	76	4.8	50.7	.	.	.	.	.	3	.	1	3.0	16
Atlanta	7.5	180	263	226	137	1.9	76.1	.	.	.	.	.	5	4	3	1.7	40
NewYork	4.2	100	157	40	4	39.3	4.0	.	.	.	.	.	.	.	.	.	.
Northwestern	5.2	125	307	220	120	2.6	96.0	.	.	1	.	19	.	.	.	.	.
Tennessee	6.3	150	82	38	29	2.8	19.3	.	.	.	.	.	.	.	.	.	.
Tulane	6.3	150	35	2	2	17.5	1.3	.	.	.	.	.	.	.	.	.	.
Pennington	7.9	190	262	87	49	5.3	25.8	1	2	2	.5	25	4	1	.	.	.
HealthPartners	12.5	300	639	474	318	2.0	106.0	.	.	1	.	8	6	5	11	.5	88
Kansas	6.3	150	415	200	124	3.3	82.7	1	5	3	.3	48	14	6	3	4.7	48
Baylor	6.3	150	209	82	43	4.9	28.7	.	.	.	.	.	.	.	.	.	.
Nebraska	5.3	126	559	296	175	3.2	138.9	.	.	.	.	.	1	1	4	.3	75
UTSouthwestern	5.0	120	118	78	43	2.7	35.8	.	1	1	.	20	.	.	.	.	.
LA	5.0	120	260	143	84	3.1	70.0	.	.	.	.	.	.	.	.	.	.
Stanford	6.3	150	328	158	91	3.6	60.7	.	.	.	.	.	1	2	2	.5	32
Baltimore	7.7	100	214	126	83	2.6	83.0	.	2	4	.	52	.	4	1	.	13
Cleveland	7.7	100	189	96	55	3.4	55.0	.	1	.	.	.	3	1	1	3.0	13
Kaiser	10.0	130	456	415	267	1.7	205.4	3	3	2	1.5	20	2	1	6	.3	60
Denver	5.4	65	338	138	81	4.2	124.6	.	4	2	.	37	5	.	2	2.5	37
Lenox	5.0	25	84	52	46	1.8	184.0	1	3	1	1.0	20	7	6	4	1.8	80
	.	.	7133	3974	2419	2.9	100.2	9	25	19	.5	14	60	39	51	1.2	37

Randomizations by Site



Biorepository Consent Rates

Site	Total RAND	Biorepository Consent (%)	DNA Consent (%)
Atlanta	137	95%	94%
Baltimore	83	93%	90%
Baylor	43	93%	93%
Beth Israel	4	75%	75%
Cleveland	56	96%	95%
Denver VA	60	98%	97%
Duke	140	81%	79%
Florida	76	96%	95%
HealthPartners	318	91%	90%
Kaiser	267	94%	92%
Lenox Hill Hospital	46	87%	87%
LA	84	88%	88%
Maine	107	89%	89%
South Carolina	32	75%	75%
MedStar	159	91%	87%
Northwestern	120	92%	88%
Omaha VA	116	91%	91%
Pennington	49	88%	86%
Stanford	91	93%	92%
Truman	13	85%	85%
Tufts	154	94%	94%
UC Denver	21	95%	95%
Kansas	111	79%	79%
Nebraska (UNMC)	59	88%	85%
Tennessee	29	62%	59%
UT Southwestern	43	100%	100%
Overall	2420	90%	89%

Demographics of Randomized Participants

Site	Total	Male	Hispanic or Latino	White	Black or African American	Asian	American Indian or Alaska Native	Native Hawaiian or Other Pacific Islander	Other
Atlanta	137	124	3	26	104	4	2	0	1
Baltimore	83	28	0	16	64	2	0	0	1
Baylor	43	14	14	24	15	0	2	1	1
Beth Israel	4	2	2	2	2	0	0	0	0
Cleveland	56	38	4	31	21	3	0	0	1
Denver VA	60	55	7	50	8	0	2	0	0
Duke	140	69	6	77	56	6	0	0	1
Florida	76	32	14	58	12	3	0	0	3
HealthPartners	318	195	9	289	14	10	2	0	3
Kaiser	267	143	22	221	14	18	1	0	13
Lenox Hill Hospital	46	22	13	24	14	6	0	0	2
LA	84	12	79	79	2	3	0	0	0
Maine	107	44	1	102	2	0	0	0	3
South Carolina	32	10	0	19	11	1	0	0	1
MedStar	159	77	7	48	100	6	1	2	2
Northwestern	120	74	7	82	31	7	0	0	0
Omaha VA	116	111	4	103	8	1	1	0	3
Pennington	49	20	1	31	16	2	0	0	0
Stanford	91	58	5	50	4	35	0	0	2
Truman	13	6	1	5	8	0	0	0	0
Tufts	154	74	8	95	42	15	0	0	2
UC Denver	21	13	1	14	7	0	0	0	0
Kansas	111	49	3	81	26	2	1	1	0
Nebraska (UNMC)	59	31	3	49	7	0	1	1	1
Tennessee	29	10	1	10	19	0	0	0	0
UT Southwestern	43	24	9	27	7	6	0	0	3
Overall	2420	1336	224	1613	616	130	13	5	43
9.3%									